91 related articles for article (PubMed ID: 30047289)
1. Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson Iii AB
Curr Med Res Opin; 2018 Dec; 34(12):2151-2156. PubMed ID: 30047289
[TBL] [Abstract][Full Text] [Related]
2. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis.
Broder MS; Cai B; Chang E; Neary MP; Papoyan E; Benson AB
Oncology; 2018; 94(5):281-288. PubMed ID: 29510379
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis.
Benson AB; Broder MS; Cai B; Chang E; Neary MP; Papoyan E
World J Gastroenterol; 2017 Sep; 23(33):6128-6136. PubMed ID: 28970728
[TBL] [Abstract][Full Text] [Related]
5. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
[TBL] [Abstract][Full Text] [Related]
10. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
12. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
14. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
[TBL] [Abstract][Full Text] [Related]
15. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors.
Tawfik B; Ray D; Moynihan M; Princic N
J Med Econ; 2021; 24(1):1337-1345. PubMed ID: 34763589
[TBL] [Abstract][Full Text] [Related]
16. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of breakthrough seizures.
Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
[TBL] [Abstract][Full Text] [Related]
18. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
20. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
